Fairvalue-Calculator Fairvalue-Calculator
EN DE

Collegium Pharmaceutical, Inc (COLL) Fair Value & Analysis

Healthcare · US · Market cap $1.1B

Price$34.62
Fair Value$42.65
Upside+23.2%
Quality95/100
Evidence: High Range $31.98 – $76.25

Fair value as of: Jun 24, 2026

Analysis

Collegium Pharmaceutical, Inc (COLL) currently trades at $34.62, while our model-based Fair Value estimate is $42.65 — implying the stock looks roughly 23.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegi…

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Collegium Pharmaceutical, Inc (COLL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $42.65 versus a price of $34.62 — about +23% (undervalued). Model-based estimate, not financial advice.
What is the fair value of COLL?
Our 21-model fair value for Collegium Pharmaceutical, Inc is $42.65 (as of Jun 24, 2026), built from audited fundamentals. The current price is $34.62.
What is the quality score of COLL?
Collegium Pharmaceutical, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.